Structural characterization of M8C10, a neutralizing antibody targeting a highly conserved prefusion-specific epitope on the metapneumovirus fusion trimerization interface

Author:

Xiao Xiao123,Wen Zhiyun1,Chen Qing4,Shipman Jennifer M.4,Kostas James4,Reid John C.4,Warren Christopher1,Tang Aimin1,Luo Bin5,O’Donnell Gregory5,Fridman Arthur6,Chen Zhifeng1,Vora Kalpit A.1,Zhang Lan1,Su Hua-Poo4,Eddins Michael J.4ORCID

Affiliation:

1. Infectious Diseases and Vaccines Discovery, Merck & Co., Inc., West Point, Pennsylvania, USA

2. Discovery Biologics, Merck & Co., Inc., Boston, Massachusetts, USA

3. MRL Postdoctoral Research Program, Merck & Co., Inc., Kenilworth, New Jersey, USA

4. Protein and Structural Chemistry, Merck & Co., Inc., West Point, Pennsylvania, USA

5. Quantitative Biosciences, Merck & Co., Inc., West Point, Pennsylvania, USA

6. Data Science and Scientific Informatics, Merck & Co., Inc., Rahway, New Jersey, USA

Abstract

ABSTRACT Human metapneumovirus (hMPV) is a major respiratory pathogen worldwide. Here, we report the crystal structure of a neutralizing antibody M8C10 isolated from human B cells that targets the viral fusion protein (hMPV-F) trimerization interface. This is a novel prefusion-specific epitope that is highly conserved across hMPV strains and other related viruses. The interactions between M8C10 and hMPV-F are largely driven by residues on the light chain with most hypermutated light chain residues on or near the interface. This highlights the immune recognition of a buried trimerization interface during the in vivo affinity maturation process. In addition, in vivo cotton rat challenge studies were performed that show M8C10 provides strong lung protection against hMPV A viral challenge. The hMPV-F:M8C10 Fab structure reported reveals a class of hMPV antibodies in the human immune repertoire with a novel neutralization mechanism, targeting the trimerization interface of hMPV-F antigen. IMPORTANCE Human metapneumovirus (hMPV) is a common pathogen causing lower respiratory tract infections worldwide and can develop severe symptoms in high-risk populations such as infants, the elderly, and immunocompromised patients. There are no approved hMPV vaccines or neutralizing antibodies available for therapeutic or prophylactic use. The trimeric hMPV fusion F protein is the major target of neutralizing antibodies in human sera. Understanding the immune recognition of antibodies to hMPV-F antigen will provide critical insights into developing efficacious hMPV monoclonal antibodies and vaccines.

Funder

Merck

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3